Strategic Partners Bilan de santé

Santé financière contrôle des critères 6/6

Strategic Partners possède un total de capitaux propres de DKK16.1M et une dette totale de DKK0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont DKK17.9M et de DKK1.8M. L'EBIT de Strategic Partners est DKK1.8M ce qui fait que son ratio de couverture des intérêts -2.1. Elle dispose de liquidités et de placements à court terme de DKK17.8M.

Informations clés

Ratio d'endettement

DKK 0

Dette

Ratio de couverture des intérêts	-2.1x
Argent liquide	DKK 17.75m
Fonds propres	DKK 16.09m
Total du passif	DKK 1.76m
Total des actifs	DKK 17.85m

Mises à jour récentes de la santé financière

Recent updates

What Type Of Shareholders Make Up Orphazyme A/S' (CPH:ORPHA) Share Registry?

Mar 04

How Many Orphazyme A/S (CPH:ORPHA) Shares Do Institutions Own?

Nov 19

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de STRAP ( DKK17.9M ) dépassent ses passifs à court terme ( DKK1.8M ).

Passif à long terme: STRAP n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: STRAP est sans dette.

Réduire la dette: STRAP n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: STRAP dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: STRAP dispose d'une marge de trésorerie suffisante pour 1.5 ans si le flux de trésorerie disponible continue de croître à un taux historique de 10.6 % chaque année.

Strategic Partners Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Orphazyme American Depositary Shares - Sponsored to Be Deleted from Other OTC

Orphazyme A/S announced delayed amended 20-F filing

Orphazyme A/S announced delayed 20-F filing

Recent updates

New minor risk - Shareholder dilution

New major risk - Share price stability

No independent directors

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO

Orphazyme A/S Announces Board Changes

Orphazyme A/S to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Orphazyme A/S Revises Earnings Guidance for the Year 2022

Orphazyme American Depositary Shares - Sponsored to Be Deleted from Other OTC

Orphazyme A/S Announces Board Appointment

Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022

KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million.

Orphazyme A/S Announces Executive Changes

Orphazyme A/S(CPSE:ORPHA) dropped from S&P Global BMI Index

Orphazyme A/S announced delayed amended 20-F filing

Orphazyme A/S announced delayed 20-F filing

Orphazyme A/S to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Orphazyme A/S, Annual General Meeting, May 21, 2022

Forecast to breakeven in 2024

Orphazyme A/S Announces Update on Regulatory Review of Arimoclomol in the European Union

Orphazyme A/S Elects Andrew Mercieca as Member of the Board of Directors

Orphazyme Provides Update for Planned NDA Resubmission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the United States

Orphazyme to Present Additional Data on Arimoclomol’s Mechanism of Action During 2022 Annual Worldsymposium™

Orphazyme A/S Announces CEO Changes

Orphazyme A/S Revises Earnings Guidance for the Year 2021

Forecast to breakeven in 2024

Orphazyme A/S Maintains its Outlook for the Full Year 2021

Price target decreased to kr.81.00

Orphazyme A/S Announces Publication of Results from Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C in the Journal of Inherited Metabolic Disease

Independent Director Martijn Kleijwegt has left the company

Independent Director Remi P. Droller has left the company

Independent Director Anders Hedegaard has left the company

CytRx Corporation Announces 24-Month Interim Results of an Open-Label Extension Trial of Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Consensus revenue estimates fall to kr.95.0m

Price target increased to kr.127

Orphazyme Provides Earnings Guidance for the Year of 2021

Orphazyme A/S Announces Topline Data from Pivotal Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

Independent Director has left the company

What Type Of Shareholders Make Up Orphazyme A/S' (CPH:ORPHA) Share Registry?

Orphazyme A/S Appoints Christophe Bourdon as Chief Executive Officer, Effective on April 1, 2021

Price target lowered to kr.135

Orphazyme A/S to Showcase Data on Arimoclomol in Niemann-Pick Disease Type C During the 2021 Annual Worldsymposium™

New 90-day high: kr.78.30

CytRx Corporation Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C

Orphazyme A/S Announces the U.S. Food and Drug Administration Has Extended the Review Period of the New Drug Application

New 90-day low: kr.56.30

Orphazyme A/S Announces Executive Changes

Orphazyme A/S, Annual General Meeting, Mar 25, 2021

Orphazyme A/S to Report First Half, 2021 Results on Aug 24, 2021

How Many Orphazyme A/S (CPH:ORPHA) Shares Do Institutions Own?

Orphazyme A/S Submits European Marketing Authorisation Application for Arimoclomol for Treatment of Niemann-Pick Disease Type C

CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol

New 90-day low: kr.66.00

Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million.

Orphazyme A/S Provides Update on Previously Announced Global Offering

Orphazyme A/S Elects Carrolee Barlow as Board of Director

New 90-day low: kr.80.60

New 90-day low - kr.87.00

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines